Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (51)

  1. Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. 2025-08-29 · Expand citations
  2. Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. 2025-07-01 · Expand citations
  3. Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care. 2025-01-01 · Expand citations
  4. Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis 2024-10-03 · Expand citations
  5. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. 2024-10-01 · Expand citations
  6. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. 2024-04-01 · Expand citations
  7. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. 2024-03-08 · Expand citations
  8. Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. 2024-01-01 · Expand citations
  9. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. 2023-12-01 · Expand citations
  10. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. 2023-09-01 · Expand citations
  11. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. 2023-04-14 · Expand citations
  12. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. 2023-02-01 · Expand citations
  13. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders. 2023-01-01 · Expand citations
  14. Group psychedelic therapy: empirical estimates of cost-savings and improved access. 2023-01-01 · Expand citations
  15. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. 2023-01-01 · Expand citations
  16. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. 2022-11-15 · Expand citations
  17. Increased global integration in the brain after psilocybin therapy for depression. 2022-04-01 · Expand citations
  18. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. 2022-02-01 · Expand citations
  19. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. 2021-05-01 · Expand citations
  20. Trial of Psilocybin versus Escitalopram for Depression. 2021-04-15 · Expand citations
  21. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2018-02-01 · Expand citations
  22. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
  23. OpenAlex W2030224179
  24. OpenAlex W2062101624
  25. OpenAlex W2113099805
  26. OpenAlex W2996555671
  27. OpenAlex W3192281797
  28. OpenAlex W3203928800
  29. OpenAlex W3209277823
  30. OpenAlex W4213145592
  31. OpenAlex W4281666404
  32. OpenAlex W4297478109
  33. OpenAlex W4307093712
  34. OpenAlex W4311508922
  35. OpenAlex W4385628167
  36. OpenAlex W4386420994
  37. OpenAlex W4386894189
  38. OpenAlex W4387521434
  39. OpenAlex W4388447053
  40. OpenAlex W4388732506
  41. OpenAlex W4391842082
  42. OpenAlex W4393253405
  43. OpenAlex W4396814296
  44. OpenAlex W4396900907
  45. OpenAlex W4398780811
  46. OpenAlex W4399323719
  47. OpenAlex W4400099913
  48. OpenAlex W4402748917
  49. OpenAlex W4403775020
  50. OpenAlex W4404764894
  51. OpenAlex W4404930798

Cited by — these papers cite this paper (0)

No citing papers identified in the available metadata. This does not establish that none exist.